Jennifer Sugg
Astellas Pharma
Internal medicineUrologyOncologyAntigenRandomized controlled trialSubgroup analysisAdverse effectPlacebo-controlled studyHazard ratioPlaceboEnzalutamideAndrogen deprivation therapyMetastasisDarolutamideProstate cancerDocetaxelProstate-specific antigenPopulationHormone sensitive prostate cancerDouble blindPost hocIn patientCastration resistantOverall survivalPhases of clinical researchClinical trialAndrogen receptorPost-hoc analysisMedicine
22Publications
5H-index
285Citations
Publications 25
Newest
#1Ugo De GiorgiH-Index: 56
#2Maha Hussain (NU: Northwestern University)H-Index: 80
Last. Joyce Steinberg (Astellas Pharma)H-Index: 13
view all 14 authors...
BACKGROUND Enzalutamide combined with androgen deprivation therapy (ADT) significantly prolonged metastasis-free survival and overall survival (OS) versus ADT alone in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) with rapidly rising prostate-specific antigen (PSA). The objective of this post hoc analysis of the PROSPER trial is to evaluate OS benefit and safety of enzalutamide in patients across age and regional subgroups. PATIENTS AND METHODS Eligible men with nmCR...
Source
#1David F. Penson (VUMC: Vanderbilt University Medical Center)H-Index: 82
#2Andrew J. Armstrong (Duke University)H-Index: 62
Last. Celestia S. Higano (Fred Hutchinson Cancer Research Center)H-Index: 88
view all 12 authors...
BACKGROUND In the phase 2, randomized, double-blind STRIVE trial, enzalutamide significantly reduced the risk of prostate cancer progression or death versus bicalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) and nonmetastatic CRPC (nmCRPC). The objective of this protocol-specified subgroup analysis of STRIVE was to investigate the benefit of enzalutamide versus bicalutamide specifically in patients with nmCRPC. METHODS Patients (N = 139) were stratified by dise...
Source
#2Ugo De GiorgiH-Index: 56
Last. Neal D. ShoreH-Index: 58
view all 8 authors...
INTRODUCTION Limited data from controlled clinical trials are available for men who experience biochemical recurrence after definitive therapy for prostate cancer. In the absence of overt metastases, patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) often receive androgen deprivation therapy (ADT). There is no standard-of-care consensus on optimal ADT timing, although most men are treated prior to metastases, especially those with high-risk features (Gleason score 8-10 o...
Source
Source
#1Taro Iguchi (OCU: Osaka City University)H-Index: 14
#2Go Kimura (Nippon Medical School)H-Index: 19
Last. Arnulf Stenzl (University of Tübingen)H-Index: 87
view all 15 authors...
Objective To evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer. Methods A post-hoc analysis of the Japanese subgroup in the phase III, randomized, multinational ARCHES study (NCT02677896) was carried out. Patients with metastatic hormone-sensitive prostate cancer were randomized to receive enzalutamide or a placebo, plus androgen deprivation therapy, stratified by disease volume and prior docetaxel...
Source
#1Filip Janku (University of Texas MD Anderson Cancer Center)H-Index: 65
#2Patricia LoRusso (Yale Cancer Center)H-Index: 83
Last. Howard A. BallH-Index: 4
view all 9 authors...
Background We assessed the safety, tolerability, and pharmacokinetics of mitochondrial complex 1 inhibitor ASP4132. Methods This phase I dose-escalation/dose-expansion study enrolled patients with treatment refractory advanced solid tumors to assess safety, dose-limiting toxicities (DLTs), efficacy and pharmacokinetic or oral ASP4132. Results Overall, 39 patients received ASP4132. Acceptable tolerability of ASP4132 5 mg in the first patient led to enrollment in the 10-mg dose cohort. After two D...
Source
94Background: The PROSPER trial demonstrated prolonged MFS and OS for men with nmCRPC and rapidly rising PSA treated with ENZA vs placebo, both in combination with androgen deprivation therapy (ADT...
Source
84Background: Previous reports on the PROSPER trial have shown that enzalutamide (ENZA) plus androgen deprivation therapy (ADT) significantly improves metastasis-free survival and overall survival ...
Source
#1Andrew M Wardley (MAHSC: Manchester Academic Health Science Centre)H-Index: 54
#2Javier CortesH-Index: 79
Last. Manon T HuizingH-Index: 4
view all 22 authors...
PURPOSE Androgen receptor (AR) expression occurs in up to 86% of human epidermal growth factor receptor 2-positive (HER2+) breast cancers. In vitro, AR inhibitors enhance antitumor activity of trastuzumab, an anti-HER2 antibody, in trastuzumab-resistant HER2+ cell lines. This open-label, single-arm, phase II study evaluated the efficacy and safety of enzalutamide, an AR-signaling inhibitor, in patients with advanced HER2+ AR+ breast cancer previously treated with trastuzumab. METHODS Eligible pa...
Source
#1Fred Saad (UdeM: Université de Montréal)H-Index: 103
#2Cora N. Sternberg (Cornell University)H-Index: 101
Last. Maha Hussain (NU: Northwestern University)H-Index: 80
view all 11 authors...
Abstract Background There is no universally accepted definition for prostate-specific antigen (PSA) progression. However, changes in PSA in patients with castration-resistant prostate cancer (CRPC) are used to inform treatment decisions. Objective To determine whether the Prostate Cancer Working Group 2 (PCWG2) definition of PSA progression is adequate to predict radiographic or clinical progression in enzalutamide-treated men with nonmetastatic CRPC (nmCRPC). Design, setting, and participants A...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.